Loading patent…
AssigneeHoffman-La Roche Inc.
InventorsThomas Friess, Christian Klein, Pamela Strein, Pablo Umana
Estimating the term…
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and an anti-Bcl-2 active agent.
A composition comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent.
A composition according to claim 8 claim 7, wherein said BcI-2 protein binding inhibitor is ABT-263 or ABT-737.
A kit comprising a type II anti-CD20 antibody and an anti-BcI-2 active agent for the combination treatment of a patient suffering from a CD20 expressing cancer.
A method for the treatment of a CD20 expressing cancer in a patient comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and an anti-BcI-2 active agent.
Dependencies are inferred from the claim text.